Editorial: Worsening Renal Function and Mortality in Heart Failure: Causality or Confounding?

Circulation: Heart Failure

Volumn 10, Issue 2, 2017, Pages

  Testani, Jeffrey M ^a   Brisco Bacik, Meredith A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardio renal syndrome; Editorials; glomerular filtration rate; heart failure; prognosis; renin angiotensin system; worsening renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CREATININE;

ACUTE HEART FAILURE; APOPTOSIS; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; WORSENING RENAL FUNCTION; HEART FAILURE;

GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 85013472540     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.003835     Document Type: Review

References (22)

1. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J. 2014;35:455-469. doi: 10.1093/eurheartj/eht386
2. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J; European Uremic Toxin Work Group. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008;19:863-870. doi: 10.1681/ASN.2007121377
3. Rosner MH, Ronco C, Okusa MD. The role of inflammation in the cardio-renal syndrome: A focus on cytokines and inflammatory mediators. Semin Nephrol. 2012;32:70-78. doi: 10.1016/j.semnephrol.2011.11.010
4. Testani JM, Cappola TP, McCauley BD, Chen J, Shen J, Shannon RP, Kimmel SE. Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization. Am Heart J. 2011;161:944-949. doi: 10.1016/j. ahj.2011.02.005
5. Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. Am J Cardiol. 2010;106:1763-1769. doi: 10.1016/j.amjcard.2010.07.050
6. Testani JM, Coca SG, McCauley BD, Shannon RP, Kimmel SE. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail. 2011;13:877-884. doi: 10.1093/eurjhf/hfr070
7. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail. 2011;4:685-691. doi: 10.1161/CIRCHEARTFAILURE.111.963256
8. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265-272. doi: 10.1161/CIRCULATIONAHA.109.933275
9. Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensinaldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail. 2013;15:1236-1244. doi: 10.1093/eurjhf/hft089
10. van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, Pinto YM. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction J Am Coll Cardiol. 2006;48:1621-1627. doi: 10.1016/j.jacc.2006.06.056
11. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985-1991
12. Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail. 2014;16:41-48. doi: 10.1002/ejhf.13
13. Beldhuis IE, Streng KW, Ter Maaten JM, Voors AA, van der Meer P, Rossignol P, McMurray JJV, Damman K. Renin-agniotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: A meta-analysis of published study data. Circ Heart Fail. 2017;10:e003588. doi: 10.1161/CIRCHEARTFAILURE.116.003588
14. Testani JM, Damman K, Brisco MA, Chen S, Laur O, Kula AJ, Tang WH, Parikh C. A combined-biomarker approach to clinical phenotyping renal dysfunction in heart failure. J Card Fail. 2014;20:912-919. doi: 10.1016/j.cardfail.2014.08.008
15. Testani JM, Coca SG, Shannon RP, Kimmel SE, Cappola TP. Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: Analysis of three randomized controlled trials. Eur J Heart Fail. 2011;13:1224-1230. doi: 10.1093/eurjhf/hfr123
16. Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail. 2011;17:993-1000. doi: 10.1016/j.cardfail.2011.08.009
17. Brisco MA, Coca SG, Chen J, Owens AT, McCauley BD, Kimmel SE, Testani JM. Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ Heart Fail. 2013;6:233-239. doi: 10.1161/CIRCHEARTFAILURE.112.968230
18. Brisco MA, Kimmel SE, Coca SG, Putt ME, Jessup M, Tang WW, Parikh CR, Testani JM. Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. Circ Heart Fail. 2014;7:68-75. doi: 10.1161/CIRCHEARTFAILURE.113.000507
19. Brisco MA, Zile MR, Hanberg JS, Wilson FP, Parikh CR, Coca SG, Tang WH, Testani JM. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J Card Fail. 2016;22:753-760. doi: 10.1016/j.cardfail.2016.06.423
20. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492-2503. doi: 10.1056/NEJMoa1306033
21. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol. 2014;64:1106-1113. doi: 10.1016/j.jacc.2014.01.087
22. Le VV, Mitiku T, Sungar G, Myers J, Froelicher V. The blood pressure response to dynamic exercise testing: A systematic review. Prog Cardiovasc Dis. 2008;51:135-160. doi: 10.1016/j.pcad.2008.07.001.